Cardiotoxicity has rarely been reported as a complication of melphalan or fludarabine administration as single agents. Recently, melphalan and fludarabine have been used in combination as non-myeloablative conditioning chemotherapy prior to allogeneic stem cell transplantation. We have observed the development of severe left ventricular failure in three of 21 patients treated with this combination. Cardiotoxicity in this context has not previously been reported and has implications for the assessment, monitoring and treatment of patients undergoing pre-transplant conditioning with melphalan and fludarabine. Bone Marrow Transplantation (2001) 28, 101-103. Keywords: emlphalan; fludarabine; BMT; cardiotoxity The alkylating agent melphalan, either alone or in combination with other agents such as busulphan and total body irradiation, has been widely used in myeloablative conditioning regimens prior to stem cell transplantation for diseases such as multiple myeloma, 1 non-Hodgkin lymphoma 2 and Hodgkin's disease. 3 The clinical utility of melphalan has recently been extended by the development of nonmyeloablative transplant regimens intended to exploit the graft-versus-tumour effect of allogeneic T cell chimerism whilst reducing the toxicities associated with myeloablative conditioning.
The alkylating agent melphalan, either alone or in combination with other agents such as busulphan and total body irradiation, has been widely used in myeloablative conditioning regimens prior to stem cell transplantation for diseases such as multiple myeloma, 1 non-Hodgkin lymphoma 2 and Hodgkin's disease. 3 The clinical utility of melphalan has recently been extended by the development of nonmyeloablative transplant regimens intended to exploit the graft-versus-tumour effect of allogeneic T cell chimerism whilst reducing the toxicities associated with myeloablative conditioning. 4 Non-myeloablative regimens have seen melphalan used in novel combinations with agents such as the purine analogue, fludarabine. 5 The application of these novel regimens is particularly attractive in patients considered too old for standard allografts.
It is conceivable that these regimens may lead to unexpected toxicities due to the cumulative or synergistic effects of the individual drugs, particularly in an older patient population. Although cardiac dysfunction is well described with other alkylating agents such as cyclophosphamide, 6 single-agent melphalan has not been shown to affect cardiac contractility in prospective studies. 7 also only been rarely associated with cardiac dysfunction, with a single report of non-fatal congestive heart failure in two of 27 patients treated for chronic lymphocytic leukaemia. 8 Conditioning regimens combining fludarabine and melphalan have been associated with veno-occlusive disease and mucosal toxicity, but development of cardiotoxicity had not been specifically assessed in earlier reports. 5, 9 Recently, in an updated series, reduced-intensity conditioning with melphalan and purine analogues was associated with the development of Bearman grade 3-4 cardiotoxicity in four of 86 patients. 10 The clinical features of cardiotoxicity in this setting have not, however, been documented. We describe the development of severe left ventricular failure (LVF) in three of 21 patients undergoing non-myeloablative stem cell transplantation (NMSCT) following conditioning with these agents.
Case reports
Twenty-one patients have undergone NMSCT following conditioning with melphalan and fludarabine at our institution for multiple myeloma (11), chronic lymphocytic leukaemia (3), chronic myeloid leukaemia (2), acute lymphoblastic leukaemia (2), non-Hodgkin lymphoma (1), acute myeloblastic leukaemia (1), and paroxysmal nocturnal haemoglobinaemia (1). All received a total fludarabine dose of 150 mg/m 2 over 5 days (day −6 to day −2 inclusive) in addition to melphalan 120 mg/m 2 (four cases) or 140 mg/m 2 (17 cases) on day −1. The average age was 49.5 years (range 20-66 years) with 13 males and eight females. All received HLA-matched sibling G-CSF mobilised peripheral blood stem cell (PBSC) allografts, with 17 receiving unmanipulated grafts and four receiving CD34 + selected grafts. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin 3 mg/kg/day and methotrexate 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, +6, +11 without folinic acid rescue following unselected grafts, and cyclosporin 3 mg/kg/day alone following CD34 + selected grafts. The average time to an absolute neutrophil count Ͼ0.5 × 10 9 /l was 16 days (range 11-23). G-CSF was not given routinely post transplant. Excluding cardiotoxicity, the combination of fludarabine and melphalan was generally well tolerated within this group with one additional patient developing fatal pulmonary toxicity (pulmonary haemorrhage).
All patients had a normal pre-BMT left ventricular ejection fraction (LVEF) as determined by gated blood pool isotope scanning. The clinical details of the three patients developing LVF are outlined in Table 1 . As determined by a modified Framingham heart study score, all patients were considered to be of low coronary heart disease risk.
11 Case 1 was transplanted with unselected PBSC, cases 2 and 3 with CD34
+ selected PBSC. At the onset of dyspnoea all patients developed clinical signs of pulmonary oedema, including inspiratory crepitations, tachypnea, tachycardia and a third heart sound. No evidence of acute sepsis was present at the onset of LVF. Blood cultures remained negative throughout the transplant course. There was no evidence of acute viral myocarditis. Electrocardiograph (ECG) demonstrated sinus tachycardia in all cases. T wave inversion in the anterolateral leads was also present in case 2. No patient developed cardiac enzyme changes. Transthoracic echocardiography was performed in all cases within 48 h of the onset of symptoms, and serially thereafter. Echocardiographic evidence of amyloidosis was not seen in either patient with myeloma.
All patients responded clinically to diuretic and angiotensin converting enzyme-inhibitor therapy, with rapid improvement in dyspnea over 48 to 72 h and full radiological resolution of pulmonary oedema over 5 to 7 days. Slow progressive recovery of cardiac ejection fraction occurred over 150 days.
Discussion
The development of severe LVF in three of 21 patients conditioned with fludarabine and melphalan conditioning contrasts with the reported rarity of cardiotoxicity with either agent individually. LVF developed in the absence of Table 1 Clinical features and sequential left ventricular ejection fraction (LVEF) of three patients developing left ventricular failure (LVF) following conditioning with melphalan and fludarabine LVEF was determined pre-transplant by gated blood pool isotope scanning and post-transplant by transthoracic echocardiography. CLL = chronic lymphocytic leukemia; MM = multiple myeloma; ACE-I = angiotensin converting enzyme-inhibitor.
other recognised aetiologies such as sepsis, fluid overload, cardiac ischemia, or pre-existing myocardial disease such as amyloidosis. No history of cardiac disease was present and each patient had normal pre-transplant cardiac function. A particular feature in these cases was the rapid onset of progressive, severe pulmonary oedema 12 to 16 days post transplant. Despite the severity of LVF, resolution of symptoms occurred in all cases and slow improvement of LV function was obtained with administration of diuretic and an ACE inhibitor. This time course and the absence of elevated cardiac enzymes are consistent with temporary functional impairment of myocardial contractility, rather than myocardial necrosis or other irreversible forms of tissue damage.
The precise role of melphalan and fludarabine in the development of cardiac dysfunction cannot be stated definitively. While there are reports of paroxysmal arrhythmia following melphalan administration, 12, 13 prospective studies have not shown that melphalan significantly affects cardiac contractility. Although fludarabine has rarely been implicated, 8 other purine analogues have shown evidence of cardiotoxicity. Three of 42 patients treated on a phase I study of the purine nucleoside analogue 3-deazaguanine developed a syndrome resembling that seen in our patients, with clinically significant subacute global left ventricular impairment in the absence of cardiac enzyme elevations or reproducible ECG changes. 14 The proposed mechanism for the cardiotoxicity of these nucleoside analogues is uncertain, as this cannot be attributed to their known actions on DNA replication and repair. Although not established for fludarabine, other nucleoside analogues, both anti-viral and cytotoxic, can undergo phosphorylation by the mitochondrial deoxyguanosine kinase resulting in impaired cellular energy metabolism. 15 As the cardiotoxicity we have observed with the combination of fludarabine and melphalan has not been seen with either agent used in isolation, despite widespread and prolonged usage, it is possible that the interaction of both agents is required for the toxic effect. There are emerging preclinical data that the combination of fludarabine and alkylating agents may impair the removal of DNA-alkylator adduct formation, 16 but the effect of this drug combination on other intracellular metabolic functions remains unexplored.
The failure of pre-BMT cardiac assessment to identify the risk of developing LVF underscores the low positive predictive value of the resting LV ejection fraction for the development of cardiotoxicity in patients undergoing highdose chemotherapy. 11, 17 This has led some authors to suggest that dynamic assessment of cardiac reserve, such as time to peak filling of the left ventricle, is a more appropriate means of detecting subtle cardiac dysfunction pre-BMT. 18 In light of the increasing number of older patients being offered NMSCT, more accurate pre-transplant stratification of cardiac risk may be required if our preliminary observations of excessive cardiotoxicity with fludarabine and melphalan are confirmed.
